Study designed to evaluate the safety and efficacy of AMG 145, in people with elevated LDL-C and not treated with any other lipid-lowering medications.To do this, AMG 145 will be compared with placebo and with ezetimibe.
- Registry ID
- EUCTR2012-001362-15
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Amgen Inc
- Start date
- 2012-08-24
- Completion date
- 2013-10-29
- Last update
- 2026-08-16
Conditions
Summary
Primary objective: To evaluate the effect of 12 weeks of subcutaneous (SC) AMG 145 monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in subjects with a 10-year Framingham risk score of 10% or less.
Locations
Related clinical trials
- A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors
- Kodo Millet Porridge and Its Effects on Gut Health and Metabolic Syndrome
- A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
- Taiwan Green Propolis for Blood Lipids and Body Fat in Patients With MASLD
- A Randomized, Open-label, Two-arm, Two-period, Multiple-dose, Study to Evaluate Pharmacokinetic Drug-drug Interaction, Safety and Tolerability of UIC202601 and UIC202602 in Healthy Volunteers
- Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD
View on source registry